Reshape Lifesciences Inc (RSLS) Directors and Executive Officers

Officers & Directors

GARY D. BLACKFORD
Director

THOMAS STANKOVICH
Senior Vice President and Chief Financial Officer (principal financial and accounting officer)

PAUL F. HICKEY
President and Chief Executive Officer (principal executive officer)

DAN W. GLADNEY
Executive Chair of the Board

LORI C. MCDOUGAL
Director

ARDA MINOCHERHOMJEE
Director ,

Reshape Lifesciences Inc currently has 18 employees.

News about Reshape Lifesciences Inc Key Personnel

ReShape Lifesciences Pioneers Innovative Approaches in Weight Loss and Diabetes Management with New Health Canada Approval and Strategic Research Collaborations

In a remarkable leap forward for obesity management and diabetes treatment, ReShape Lifesciences has recently garnered Health Canada’s approval for its next-generation Lap-Band 2.0, equipped with the innovative FLEX Technology. Designed with the patient s experience at the forefront, this advanced device promises to enhance safety, comfort, and efficacy during weight-loss procedures. The approval is a significant milestone for ReShape, as it not only reflects the company s commitment to improving patient outcomes but also aligns with its vision of utilizing state-of-the-art technology to tackle pressing health challenges.The FLEX Technology incorporated in the Lap-Band 2.0 aims to redefine the patient expe...

Reshape Lifesciences: A Promising Rebirth towards Profitability in the Healthcare Market

Reshape Lifesciences: A Promising Turnaround in the Making
In a recent announcement, Reshape Lifesciences provided an update on its 2024 cost reduction plan and reorganization strategy, signaling a significant shift towards the commercialization of its Lap-Band 2.0 FLEX. With the aim of prioritizing profitability, the company expects operating expenses to decrease by a staggering 55.4% compared to the previous year.
However, the path leading up to this point has been marred by financial challenges. Reshape Lifesciences recorded a cumulative net loss of $26 million during the 12-month period ending in the third quarter of 2023. This dismal performance resulted in a negative return on investment (...